BCAB | BioAtla, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.6303 - 0.6597
52 Week Range	0.5700 - 4.02
Beta	0.90
Implied Volatility	327.86%
IV Rank	76.10%
Day's Volume	444,485
Average Volume	1,378,300
Shares Outstanding	58,024,700
Market Cap	37,135,808
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-12-16

Valuation
Profitability
Growth
Health
P/E Ratio	-0.38
Forward P/E Ratio	N/A
EPS	-1.70
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	65
Country	USA
Website	BCAB

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

BCAB's peers: ALXO, APLT, AURA, PMVP, CCCC, NAUT, IPSC, PASG, IKNA, OLMA, AVTE, ADAG, ACRV, RZLT, ANTX, GRCL, THRX, GLUE, DSGN, ERAS, FHTX, STTK, KYMR, NRIX, BCLI, CLDX, CRBP, EQ, GLYC, IMTX, THTX, TRVI, VINC, OABI

*Chart delayed

Analyzing fundamentals for BCAB we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see BCAB Fundamentals page.

Watching at BCAB technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on BCAB Technicals page.